Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmpeak Energy Regulatory News (AMP)

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes
Get Live Data
2.90    0.00 (0.00%)
Bid:
2.70
Ask:
3.10
Spread: 0.40 (14.815%)
Market Cap: £20.96m
AMP Live PriceLast checked at - London Stock Exchange

Intraday Ampeak Energy Share Chart

Director/PDMR Shareholding

7 Apr 2014 17:03

RNS Number : 2618E
Kromek Group PLC
07 April 2014
 



For immediate release: 7 April 2014

Kromek Group plc ("Kromek" or "the Company")

Director / PDMR shareholding

The Company was informed today that Richard Morgan, Chairman of the Company, purchased 40,000 Ordinary Shares ("Shares") of 1p each at an average of 50p per share on 07 April 2014, representing 0.04 per cent of the Company's total issued share capital.

Mr Morgan's total holding in the Company is now 372,310 Shares of 1p each, representing 0.35 per cent of the Company's total issued share capital.

Mr Morgan is also interested in Amphion Innovations plc through his Directorship in Amphion Innovations plc which holds 12,450,420 ordinary shares in Kromek being 11.6 per cent of the Company's total issued share capital.

-ends-

 

For further information, please contact:

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

 

Tel: 01740 626060

Panmure Gordon

As Nominated Adviser and Broker

Corporate Finance

Freddy Crossley

Broking

Adam Pollock/ Charles Leigh-Pemberton

 

Tel: 020 7886 2500

Tavistock Communications

Matt Ridsdale / Andrew Dunn

Tel: 020 7920 3150

 

About Kromek Group plc

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 70 granted patents and 110 pending applications.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSQKODPPBKDFQK
Date   Source Headline
17th Feb 20267:06 amRNSTR-1 NOTIFICATION OF MAJOR HOLDINGS
17th Feb 20267:00 amRNSUltimate Beneficial Owner Notification
19th Jan 20269:31 amRNSMey BESS planning
18th Dec 202511:34 amRNS-ROffshore works completed at MeyGen site
20th Nov 20257:00 amRNSCCR funding completed
10th Nov 202510:34 amRNS-RAmpeak Energy welcomes Cabinet Secretary to MeyGen
4th Nov 20257:00 amRNS-RAmpeak Energy Investor Day
13th Oct 20259:08 amRNSAW2 Battery Project receives formal planning
7th Oct 20257:00 amRNSAmpeak Energy Investor Day
1st Oct 202512:46 pmRNSAmpeak Energy achieves planning permission for AW2
30th Sep 202510:23 amRNSDirector/PDMR Shareholding
26th Sep 20257:00 amRNSAmpeak Energy Interim Results
22nd Sep 202512:09 pmRNS-RAmpeak Energy hosts AW1 Groundbreaking Ceremony
31st Dec 20191:15 pmRNSAmphion Innovations
31st Dec 201912:36 pmRNSCancellation of trading on AIM
20th Nov 20197:00 amRNSDirectors' Dealings and Business Update
18th Oct 20197:00 amRNSSettlement of loan facility
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
11th Oct 20197:00 amRNSSale of Partner Company Shares
3rd Oct 20197:00 amRNSSale of Partner Company Shares
25th Sep 20197:00 amRNSAmended Terms on Loan Facility
10th Sep 20194:56 pmRNSSale of Partner Company Shares
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
9th Aug 20194:14 pmRNSDirectorate Change
9th Aug 20193:51 pmRNSSale of Partner Company Shares
1st Jul 20197:30 amRNSSuspension - Amphion Innovations Plc
27th Jun 20193:00 pmRNSAnnual Report and Accounts Update
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20197:00 amRNSLoan facility update
31st May 201910:28 amRNSHolding(s) in Company
20th May 20196:14 pmRNSHolding(s) in Company
1st Apr 20194:40 pmRNSSecond Price Monitoring Extn
1st Apr 20194:35 pmRNSPrice Monitoring Extension
1st Apr 20197:00 amRNSUpdate on Loan Facility
20th Mar 20197:00 amRNSHolding(s) in Company
19th Mar 20192:33 pmRNSSale of Partner Company Shares
18th Mar 20192:00 pmRNSPrice Monitoring Extension
15th Mar 20197:01 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSSale of Partner Company Shares
11th Mar 20194:41 pmRNSAmended Terms on Loan Facility
26th Feb 20197:00 amRNSConvertible Promissory Note Extended
14th Feb 20198:00 amRNSStatement re. Motif Bio plc
7th Feb 20199:40 amRNSStmnt re Share Price Movement
1st Feb 20197:00 amRNSAppointment of Joint Broker
21st Jan 20197:00 amRNSWellGen Finalises License Agreement
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
16th Oct 20187:00 amRNSExtended Repayment and Draw Down on Loan Facility
28th Sep 20187:00 amRNSHalf-year Report
5th Sep 20187:00 amRNSBoard Change
23rd Aug 20183:20 pmRNSPolarean update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.